Purple Biotech Ltd. - ADR

The momentum for this stock is not very good. Purple Biotech Ltd. - ADR is not a good value stock. Purple Biotech Ltd. - ADR is not very popular among insiders. Tradey thinks it is not wise to invest in Purple Biotech Ltd. - ADR.
Log in to see more information.
PPBT Fundamental Data by TradingView

News

Purple Biotech Announces ADS Ratio Change
Purple Biotech Announces ADS Ratio Change

TipRanks Financial Blog Purple Biotech (PPBT) has released an update. Purple Biotech Ltd. has announced a change in the ratio of its American Depositary Shares (ADSs) to regain compliance ...\n more…

Purple Biotech to present data for CM24 at AACR Special Conference
Purple Biotech to present data for CM24 at AACR Special Conference

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

Globe Newswire REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...\n more…

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...\n more…

What Makes Purple Biotech (PPBT) a New Buy Stock
What Makes Purple Biotech (PPBT) a New Buy Stock

Zacks Investment Research Purple Biotech Ltd. Sponsored ADR (PPBT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings...\n more…

Purple Biotech Ltd Forecasted to Post Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:PPBT)
Purple Biotech Ltd Forecasted to Post Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:PPBT)

Ticker Report Purple Biotech Ltd (NASDAQ:PPBT - Free Report) - Equities researchers at HC Wainwright increased their Q3 2024 EPS estimates for Purple Biotech in a research report issued on Monday, August 19th. HC...\n more…